Marinus Pharmaceuticals Inc (NASDAQ:MRNS)’s share price hit a new 52-week high during trading on Thursday . The company traded as high as $8.75 and last traded at $6.19, with a volume of 1530000 shares. The stock had previously closed at $6.69.
MRNS has been the subject of a number of recent research reports. ValuEngine downgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. JMP Securities reissued an “outperform” rating and issued a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 12th. Finally, BidaskClub downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday.
Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.02.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.